SCHEMBL4435115

SCHEMBL4435115

CC(C)(C)OC(=O)ON1CC(O)C(NC(=O)c2ccc(Cl)s2)C1

nearest known ligand 0.42

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
F10 P00742 19/20 0.42
F2 P00734 3/20 0.39
F11 P03951 3/20 0.39
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4435200 0.89 F10 (0.44) F10F2F11LMNAMAPK1
SCHEMBL4435125 0.87 F10 (0.41) F10F2F11
SCHEMBL3448718 0.83 F10 (0.50) F10F2F11
SCHEMBL4441725 0.83 F10 (0.41) F10F2F11
SCHEMBL4582592 0.81 F10 (0.42) F10F2LMNAMAPK1KMT2A
SCHEMBL3448759 0.74 F10 (0.51) F10F2F11
SCHEMBL4436565 0.73 F10 (0.42) F10F2F11LMNAMAPK1
SCHEMBL3308832 0.73 F10 (0.49) F10F2F11
SCHEMBL3308826 0.73 F10 (0.49) F10F2F11
SCHEMBL3447348 0.73 F10 (0.49) F10F2F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132193-B1 SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS BOEHRINGER INGELHEIM INT (DE) 2012-10-24 EP disclosed
EP-2132193-A1 SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS Boehringer Ingelheim International GmbH (DE) 2009-12-16 EP disclosed
WO-2008116881-A1 SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-02 WO disclosed
EP-1975165-A1 Substituted pyrrolidinamides, their production and utilisation as medicine Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2008-10-01 EP disclosed